1. Home
  2. ATYR vs ASRT Comparison

ATYR vs ASRT Comparison

Compare ATYR & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo aTyr Pharma Inc.

ATYR

aTyr Pharma Inc.

HOLD

Current Price

$0.85

Market Cap

69.2M

Sector

Health Care

ML Signal

HOLD

Logo Assertio Holdings Inc.

ASRT

Assertio Holdings Inc.

BUY

Current Price

$11.54

Market Cap

76.0M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
ATYR
ASRT
Founded
2005
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.2M
76.0M
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
ATYR
ASRT
Price
$0.85
$11.54
Analyst Decision
Hold
Strong Buy
Analyst Count
8
1
Target Price
$4.20
$35.00
AVG Volume (30 Days)
1.4M
24.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
95.07
EPS
N/A
N/A
Revenue
N/A
$124,961,000.00
Revenue This Year
$9,628.95
N/A
Revenue Next Year
$156.94
$1.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.64
$0.51
52 Week High
$7.29
$12.95

Technical Indicators

Market Signals
Indicator
ATYR
ASRT
Relative Strength Index (RSI) 43.50 50.67
Support Level $0.82 $11.05
Resistance Level $0.85 $12.45
Average True Range (ATR) 0.07 0.46
MACD -0.02 -0.15
Stochastic Oscillator 7.78 38.46

Price Performance

Historical Comparison
ATYR
ASRT

About ATYR aTyr Pharma Inc.

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About ASRT Assertio Holdings Inc.

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Share on Social Networks: